ORIC Pharmaceuticals

ORIC · Nasdaq · United States

Share price · ORIC

$7.65-6.27 (-45.04%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ORIC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 26 Oct 2026-32.0%
  2. 4 Aug 2026+27.1%
  3. 24 Jul 2026+11.1%
  4. 2 Apr 2026+18.9%
  5. 1 Apr 2026-41.0%
  6. 9 Mar 2026-15.0%
  7. 24 Feb 2026+14.6%
  8. 28 Jan 2026-9.3%
  9. 14 Jan 2026+10.9%
  10. 13 Jan 2026+10.8%

Share of unusual movement by asset

For each asset, the share of ORIC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Enozertinib
events and moves
3shown from 8 days
Rinzimetostat
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—8%
Other company news (earnings, financing, releases naming no asset)—35%
Sessions with no dated event—56%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
EED (PRC2)Small molecule
Prostate Cancer
Phase 1/2
EGFR/HER2Small molecule
Non-Small Cell Lung Cancer
Phase 1
CD73Small molecule
Multiple Myeloma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
EnozertinibPhase 1/2Solid Tumors
Est. primary completion 2027-06 · NCT05315700 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
RinzimetostatPhase 3Metastatic Castration Resistant Prostate Cancer
Est. primary completion 2028-03 · NCT07723248 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$36M$38M+ $227M short-term inv.$41M-$32M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$31M$57M+ $226M short-term inv.$36M-$32M operating cash flowreport ↗
2025-Q3—$29M$50M+ $237M short-term inv.$33M-$25M operating cash flowreport ↗
2025-Q2—$31M$76M+ $207M short-term inv.$36M-$31M operating cash flowreport ↗
2025-Q1—$25M$50M+ $154M short-term inv.$30M-$33M operating cash flowreport ↗
2024-Q3—$31M$45M+ $228M short-term inv.$35M-$29M operating cash flowreport ↗
2024-Q2—$29M$50M+ $237M short-term inv.$32M-$26M operating cash flowreport ↗
2024-Q1—$22M$57M+ $260M short-term inv.$25M-$30M operating cash flowreport ↗
2023-Q3—$22M$27M+ $201M short-term inv.$25M-$20M operating cash flowreport ↗
2023-Q2—$19M$104M+ $160M short-term inv.$23M-$21M operating cash flowreport ↗
2023-Q1—$20M$59M+ $131M short-term inv.$24M-$21M operating cash flowreport ↗
2022-Q3—$15M$30M+ $165M short-term inv.$25M-$19M operating cash flowreport ↗
2022-Q2—$14M$50M+ $178M short-term inv.$20M-$18M operating cash flowreport ↗
2022-Q1—$17M$113M+ $122M short-term inv.$23M-$23M operating cash flowreport ↗
2021-Q3—$13M$242M+ $48M short-term inv.$18M-$12M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$110M$46M+ $236M short-term inv.$32M-$111M operating cash flowreport ↗

For fiscal year 2025, ORIC Pharmaceuticals did not disclose revenue. R&D expenses were $109.8 million, down 3.7% YoY from $114.1 million, while cash, cash equivalents and investments totaled $392.3 million as of December 31, 2025. The company reported a net loss of $129.47 million for the year.

ORIC guided that its cash and investments are expected to fund operations into 2H 2028, and it raised $264 million from healthcare specialist funds during the year. Clinical highlights included rinzimetostat Phase 1b data in mCRPC showing PSA and ctDNA responses, with provisional recommended Phase 2 doses selected and dose optimization initiated with AR inhibitors, and enozertinib Phase 1b data in EGFR exon 20 and PACC-mutant NSCLC showing systemic and intracranial activity, with a Phase 3 monotherapy dose selected and a collaboration with Johnson & Johnson to evaluate combination with SC amivantamab. The company expects multiple clinical data readouts in 2026 and plans to initiate its first global Phase 3 registrational trial for rinzimetostat in 1H 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$114M$60M+ $197M short-term inv.$32M-$113M operating cash flowreport ↗
2023-FY—$85M$24M+ $185M short-term inv.$25M-$86M operating cash flowreport ↗
2022-FY—$62M$67M+ $139M short-term inv.$22M-$75M operating cash flowreport ↗
2021-FY—$57M$226M+ $11M short-term inv.$20M-$60M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($3.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-20Piscitelli Dominic · Chief Financial OfficerOption exercise14,000$4.36$61KForm 4
2026-10-20Piscitelli Dominic · Chief Financial OfficerOpen-market sale14,000$13.53$189KForm 4
2026-10-20Piscitelli Dominic · Chief Financial OfficerOption exercise (derivative)14,000——Form 4
2026-10-01Heyman Richard A. · directorOption exercise3,500$1.60$6KForm 4
2026-10-01Heyman Richard A. · directorOpen-market sale3,500$12.91$45KForm 4
2026-10-01Heyman Richard A. · directorOpen-market sale3,200$12.91$41KForm 4
2026-10-01Heyman Richard A. · directorOption exercise (derivative)3,500——Form 4
2026-09-28Piscitelli Dominic · Chief Financial OfficerOption exercise13,400$4.36$58KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 182 reporting institutions held 119.4M shares ($1.4B, 115.2% of shares outstanding).

#InstitutionSharesValue
1Nextech Invest, Ltd.7,162,637$90.8M
2EcoR1 Capital, LLC6,728,116$85.2M
3BlackRock, Inc.5,984,552$75.8M
4VIKING GLOBAL INVESTORS LP5,824,533$73.8M
5SR One Capital Management, LP4,514,929$58.5M
6Pfizer Inc4,780,401$57.7M
7ALKEON CAPITAL MANAGEMENT LLC4,504,096$57.1M
8Venrock Adviser, LLC4,319,765$54.7M
9NEA Management Company, LLC4,118,621$52.2M
10STATE STREET CORP3,702,196$46.9M
11VANGUARD CAPITAL MANAGEMENT LLC3,687,007$46.7M
12Column Group LLC3,540,777$44.9M
13Siren, L.L.C.2,998,192$38.0M
14ORBIMED ADVISORS LLC2,693,929$34.1M
15AIHC Capital Management Ltd2,459,551$31.2M